Polymeric Linker Antibody-Drug Conjugates High DAR Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) are limited by low drug-to-antibody ratios (DARs), which restrict their therapeutic index and the range of drugs that can be used, leading to adverse reactions and instability in aqueous solutions.
Innovation Solution
The development of an antibody-drug conjugate that incorporates a specific polymeric linker, enabling high drug-to-antibody ratios (DAR) of up to 20 or more biologically active molecules per antibody, while maintaining stability and solubility in aqueous solutions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If conventional ADCs use traditional linkers with low DAR (3-4), then the ADC structure is simpler and easier to manufacture, but the therapeutic index is limited and the range of usable drugs is restricted
Solution Approach 1:
The patent divides the traditional single-linker structure into a modular polymeric linker system with repeating units. Each repeat unit can independently carry a drug molecule, allowing the linker to be segmented into multiple functional modules that can be customized for different therapeutic needs, thereby increasing versatility without proportionally increasing overall complexity
Solution Approach 2:
The patent employs a composite polymeric linker structure combining hydrophilic segments (for solubility and stability) with drug-carrying segments (for high DAR). This composite approach allows the linker to simultaneously achieve multiple functions: high drug capacity, aqueous solubility, and structural stability, resolving the contradiction between complexity and versatility
2Adaptability or versatility
If the DAR is increased to improve therapeutic index, then more drugs can be delivered per antibody, but aggregation of the ADC occurs rendering it ineffective
Solution Approach 1:
The patent changes the physicochemical parameters of the linker by incorporating hydrophilic polymeric segments with specific molecular weights and compositions. This parameter modification increases aqueous solubility and reduces hydrophobic interactions that lead to aggregation, allowing high DAR (up to 20+) to be achieved without compromising ADC stability
Solution Approach 2:
The polymeric linker acts as an intermediary between the antibody and the multiple drug molecules. This intermediary structure provides spacing and solubility that prevents direct drug-drug or drug-antibody aggregation, mediating the interaction to maintain stability even at high drug loads
3Ease of manufacture
If conventional ADCs use limited linker structures, then manufacturing is simpler, but aqueous solubility and stability are compromised
Solution Approach 1:
The patent designs a universal polymeric linker platform with repeating units that can be synthesized once and then used to create multiple ADC variants by varying only the drug payload. This multi-functional linker structure provides solubility, stability, and high DAR capability across different drug-antibody combinations, reducing overall manufacturing complexity despite the enhanced functionality
Solution Approach 2:
The patent modifies linker parameters by selecting specific polymeric repeat units with controlled molecular weights and hydrophilicities. These parameter changes optimize aqueous solubility and stability while maintaining compatibility with standard conjugation chemistry, balancing manufacturability with improved physicochemical properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the therapeutic index of ADCs, allows for the use of a broader range of drugs, and improves patient tolerance by reducing adverse reactions, while ensuring stability and effective drug release.
Implementation Method 1
Different types of covalent linkage will hydrolyse under different conditions of (e.g.) pH, enzyme
Data Source
AI summary
The present invention relates to antibody-drug conjugates comprising (i) an antibody or antigen-binding fragment thereof, (ii) a polymer comprising a particular repeat unit comprising an amino acid derivative, which is covalently bound to one or more biologically active moieties, such as small molecule drugs, optionally via a linker, and (iii) a polymer-antibody linker moiety which is covalently bound to both the polymer and the antibody or antigen-binding fragment thereof. Additionally, the present invention relates to pharmaceutical compositions comprising the antibody-drug conjugates and to use of the antibody-drug conjugates in medicine.